Earnings$MRK6:32 AM ET3 wires · v3

Merck Q3 adj. EPS $2.49 beats $2.07, lifts FY guidance

By BORSA NewsroomPublished Oct 29, 2026, 6:32 AM EDTUpdated Oct 29, 2026, 6:34 AM EDT

Merck Q3 beat on top and bottom lines. Keytruda, Gardasil, and Winrevair all beat estimates. FY sales and EPS guidance raised. Pipeline updates include sac-TMT priority review and positive cancer vaccine data.

Sentimentbullish 80

Strongly bullish · 80 of 100

Impact80

high · market-wide

Confidence95%

high confidence · 3 wires

Eventconfirmed

v3 · alerted as breaking

WHAT WE KNOW

Q3 adj. EPS $2.49 vs est. $2.07
Q3 revenue $18.09B vs est. $17.31B
Keytruda revenue $8.60B vs est. $8.38B